Moreover, this interaction has the potential to upregulate the expression of P-glycoprotein through the mitogen-activated protein kinase pathway downstream of PI3K/AKT and PD-L1, consequently conferring drug resistance to tumor cells [98]. The gene discussed is AKT1; the disease is neoplasm.